Latest News-Lingke Pharmaceutical Mediaroom_Page

Lynk Pharmaceuticals Announces Positive Results from Phase 1b Clinical Study of LNK01004 for the Treatment of Atopic Dermatitis

HANGZHOU, China and SHANGHAI and BOSTON, Aug. 13, 2024 /PRNewswire/ -- Lynk Pharmaceuticals Co., Lt...

2024-08-13 08:00 1905

Lynk Pharmaceuticals Announces First Atopic Dermatitis Patient Dosed in Phase Ⅲ Clinical Study of LNK01001

BOSTON and HANGZHOU and SHANGHAI, China, March 22, 2024 /PRNewswire/ -- Lynk Pharmaceuticals Co., L...

2024-03-22 08:00 2591

Lynk Pharmaceuticals Announced First Rheumatoid Arthritis Patient Dosed in Phase Ⅲ Clinical Study of LNK01001

BOSTON and HANGZHOU and SHANGHAI, China, Dec. 20, 2023 /PRNewswire/ -- Lynk Pharmaceuticals Co., Lt...

2023-12-20 08:00 2688

Lynk Pharmaceuticals Completes Series C2 Financing Round, with Total C Round Funding of 322 Million RMB

HANGZHOU, China, Sept. 21, 2023 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referre...

2023-09-21 08:00 2737

Lynk Pharmaceuticals Announces Positive Topline Data from Phase II Clinical Trial of LNK01001 in the Treatment of Ankylosing Spondylitis

HANGZHOU, China, Aug. 23, 2023 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (referred to as "Lynk...

2023-08-23 08:00 3165

Lynk Pharmaceuticals Announced Positive Topline Data from Phase II Clinical Trial of LNK01001 in the Treatment of Atopic Dermatitis

HANGZHOU, China, Aug. 9, 2023 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred ...

2023-08-09 08:00 3099

Lynk Pharmaceuticals Announces First Atopic Dermatitis Patient Dosed with LNK01004 in Phase Ib Clinical Study

HANGZHOU, China, July 21, 2023 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred...

2023-07-21 08:00 2984

Lynk Pharmaceuticals Completes 200 Million RMB Series C1 Financing to Accelerate Clinical Development of Core Products

HANGZHOU, China, May 31, 2023 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred ...

2023-05-31 08:25 4071

Lynk Pharmaceuticals Announces First Cohort of Psoriatic Patients Dosed with LNK01004 in Phase Ib Clinical Study

HANGZHOU, China, May 25, 2023 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred ...

2023-05-25 08:00 4742

LYNK's LNK01001 Achieved Exciting Phase II Results in Rheumatoid Arthritis

HANGZHOU, China, May 16, 2023 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred ...

2023-05-16 08:00 4206

Lynk Pharmaceuticals Announces Positive Results for LNK01003 in Phase I Trial in Healthy Subjects

HANGZHOU, China, April 4, 2023 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred...

2023-04-04 20:00 2859

Lynk Pharmaceuticals Announces Positive Results for LNK01003 in Phase I Trial in Healthy Subjects

HANGZHOU, China, April 4, 2023 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred...

2023-04-04 08:00 2913

Lynk Pharmaceuticals Announces First Patient Dosed in Phase Ⅱ Clinical Study of LNK01003 in Patients with Ulcerative Colitis

HANGZHOU, China, Dec. 5, 2022 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred ...

2022-12-05 08:00 2734

Lynk Pharmaceuticals Announces IND Approval of LNK01004 for Atopic Dermatitis in China

HANGZHOU, China, Aug. 3, 2022 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred ...

2022-08-03 08:00 2735

Lynk Pharmaceuticals Announces the First Participant Dosed in Phase I Trial of LNK01004

HANGZHOU, China, July 29, 2022 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referre...

2022-07-29 10:00 3614

Lynk Pharmaceuticals Announces Clinical Approval in China for Its Class I New Drug LNK01004

HANGZHOU, China, April 22, 2022 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referre...

2022-04-22 08:00 3049

Lynk Pharmaceuticals and Simcere announced Strategic Commercialization Partnership upon novel JAK1 inhibitor LNK01001

HANGZHOU, China, March 18, 2022 /PRNewswire/ -- On March 18, 2022, Lynk Pharmaceuticals Co., Ltd. (...

2022-03-18 13:28 5810

Lynk Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Study of LNK01001 in Patients with Atopic Dermatitis

HANGZHOU, China, Feb. 28, 2022 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred...

2022-02-28 08:00 3139

Lynk Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Study of LNK01001 in Patients with Ankylosing Spondylitis

HANGZHOU, China, Jan. 19, 2022 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred...

2022-01-19 08:00 3056

Lynk Pharmaceuticals Announced First Patient Dosed in Phase II Clinical Study of LNK01001

HANGZHOU, China, Dec. 1, 2021 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred ...

2021-12-01 08:00 3540